Cancer Genetics Shares New Study Results on PD-L1 Candidate

Cancer Genetics (NASDAQ:CGIX) posted the results of a new study on its candidate PD-L1.
As quoted in the press release:

The study compared performance of multiple antibody clones against PD-L1 and the current standard diagnostic modality, immunohistochemistry (IHC), to an in-situ hybridization (ISH), using RNAscope®¹ approach to determine the expression of PD-L1 in diffuse large B-cell lymphoma (DLBCL) cells, a particularly aggressive form of lymphoma. Although the two modalities demonstrated relative concordance related to the identification of PD-L1 expression, there were differences that indicated that RNA-ISH may be the superior approach. First, RNA-ISH appeared to be more sensitive, identifying cases of PD-L1 expression that were negative using IHC. Second, high PD-L1 expression identified by RNA-ISH, but not IHC, was highly correlated with non-germinal center B-cell subtype, gains at the PD-L1/9p24 locus (a predictor of PD-L1 inhibitor response) and demonstrated a trend toward worse overall survival. The study demonstrates that choice and integration of diagnostic modalities can provide key additional information to assist oncologists to more accurately select therapeutic options for their patients.

Click here to read the full press release.

Source: globenewswire.com